Transcatheter closure of perimembranous ventricular septal defects using the new Amplatzer Membranous VSD Occluder

Results of the U.S. phase I trial

Yun Ching Fu, John Bass, Zahid Amin, Wolfgang Radtke, John P. Cheatham, William E. Hellenbrand, David Balzer, Qi Ling Cao, Ziyad M. Hijazi

Research output: Contribution to journalArticle

195 Citations (Scopus)

Abstract

OBJECTIVES: This phase I study attempted to report the initial safety and efficacy results of transcatheter closure of perimembranous ventricular septal defects (PmVSDs) using the new Amplatzer Membranous VSD Occluder (AGA Medical Corp., Golden Valley, Minnesota) in the U.S. BACKGROUND: The most common congenital heart disease is PmVSD. Surgical repair is widely accepted, but still carries a small but definite risk of morbidity and mortality. METHODS: Between October 2003 and August 2004, a total of 35 patients with PmVSD underwent an attempt of transcatheter closure under transesophageal and/or intracardiac echocardiographic guidance. The median age was 7.7 years (range, 1.2 to 54.4 years) and median weight was 25 kg (range, 8.3 to 110 kg). The median Qp/Qs ratio was 1.8 (range, 1 to 4), and the median VSD size as assessed by echocardiography was 7 mm (range, 4 to 15 mm). RESULTS: The attempt to place a device was successful in 32 patients (91%). The median device size used was 10 mm (range, 6 to 16 mm). The complete closure rates by echocardiography at 10 min (transesophageal/intracardiac), 24 h, 1 month, and 6 months (transthoracic) were 47% (15/32), 63% (20/32), 78% (25/32), and 96% (27/28), respectively. The median fluoroscopy time was 36 min (range, 14 to 191 min), and the median total procedure time was 121 min (range, 67 to 276 min). Three patients (8.6%) had serious adverse events of complete heart block, peri-hepatic bleeding, and rupture of tricuspid valve chordae tendineae. No other patient encountered serious adverse events during the follow-up. CONCLUSIONS: Transcatheter closure of a PmVSD is technically feasible and seems safe enough in children over 8 kg in weight to warrant continuation of clinical trials to assess the long-term safety and efficacy.

Original languageEnglish (US)
Pages (from-to)319-325
Number of pages7
JournalJournal of the American College of Cardiology
Volume47
Issue number2
DOIs
StatePublished - Jan 17 2006

Fingerprint

Ventricular Heart Septal Defects
Echocardiography
Chordae Tendineae
Safety
Weights and Measures
Equipment and Supplies
Heart Block
Tricuspid Valve
Fluoroscopy
Rupture
Heart Diseases
Clinical Trials
Hemorrhage
Morbidity
Mortality
Liver

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Transcatheter closure of perimembranous ventricular septal defects using the new Amplatzer Membranous VSD Occluder : Results of the U.S. phase I trial. / Fu, Yun Ching; Bass, John; Amin, Zahid; Radtke, Wolfgang; Cheatham, John P.; Hellenbrand, William E.; Balzer, David; Cao, Qi Ling; Hijazi, Ziyad M.

In: Journal of the American College of Cardiology, Vol. 47, No. 2, 17.01.2006, p. 319-325.

Research output: Contribution to journalArticle

Fu, Yun Ching ; Bass, John ; Amin, Zahid ; Radtke, Wolfgang ; Cheatham, John P. ; Hellenbrand, William E. ; Balzer, David ; Cao, Qi Ling ; Hijazi, Ziyad M. / Transcatheter closure of perimembranous ventricular septal defects using the new Amplatzer Membranous VSD Occluder : Results of the U.S. phase I trial. In: Journal of the American College of Cardiology. 2006 ; Vol. 47, No. 2. pp. 319-325.
@article{d95b6af75b26424daa10e76d99329ea4,
title = "Transcatheter closure of perimembranous ventricular septal defects using the new Amplatzer Membranous VSD Occluder: Results of the U.S. phase I trial",
abstract = "OBJECTIVES: This phase I study attempted to report the initial safety and efficacy results of transcatheter closure of perimembranous ventricular septal defects (PmVSDs) using the new Amplatzer Membranous VSD Occluder (AGA Medical Corp., Golden Valley, Minnesota) in the U.S. BACKGROUND: The most common congenital heart disease is PmVSD. Surgical repair is widely accepted, but still carries a small but definite risk of morbidity and mortality. METHODS: Between October 2003 and August 2004, a total of 35 patients with PmVSD underwent an attempt of transcatheter closure under transesophageal and/or intracardiac echocardiographic guidance. The median age was 7.7 years (range, 1.2 to 54.4 years) and median weight was 25 kg (range, 8.3 to 110 kg). The median Qp/Qs ratio was 1.8 (range, 1 to 4), and the median VSD size as assessed by echocardiography was 7 mm (range, 4 to 15 mm). RESULTS: The attempt to place a device was successful in 32 patients (91{\%}). The median device size used was 10 mm (range, 6 to 16 mm). The complete closure rates by echocardiography at 10 min (transesophageal/intracardiac), 24 h, 1 month, and 6 months (transthoracic) were 47{\%} (15/32), 63{\%} (20/32), 78{\%} (25/32), and 96{\%} (27/28), respectively. The median fluoroscopy time was 36 min (range, 14 to 191 min), and the median total procedure time was 121 min (range, 67 to 276 min). Three patients (8.6{\%}) had serious adverse events of complete heart block, peri-hepatic bleeding, and rupture of tricuspid valve chordae tendineae. No other patient encountered serious adverse events during the follow-up. CONCLUSIONS: Transcatheter closure of a PmVSD is technically feasible and seems safe enough in children over 8 kg in weight to warrant continuation of clinical trials to assess the long-term safety and efficacy.",
author = "Fu, {Yun Ching} and John Bass and Zahid Amin and Wolfgang Radtke and Cheatham, {John P.} and Hellenbrand, {William E.} and David Balzer and Cao, {Qi Ling} and Hijazi, {Ziyad M.}",
year = "2006",
month = "1",
day = "17",
doi = "10.1016/j.jacc.2005.09.028",
language = "English (US)",
volume = "47",
pages = "319--325",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "2",

}

TY - JOUR

T1 - Transcatheter closure of perimembranous ventricular septal defects using the new Amplatzer Membranous VSD Occluder

T2 - Results of the U.S. phase I trial

AU - Fu, Yun Ching

AU - Bass, John

AU - Amin, Zahid

AU - Radtke, Wolfgang

AU - Cheatham, John P.

AU - Hellenbrand, William E.

AU - Balzer, David

AU - Cao, Qi Ling

AU - Hijazi, Ziyad M.

PY - 2006/1/17

Y1 - 2006/1/17

N2 - OBJECTIVES: This phase I study attempted to report the initial safety and efficacy results of transcatheter closure of perimembranous ventricular septal defects (PmVSDs) using the new Amplatzer Membranous VSD Occluder (AGA Medical Corp., Golden Valley, Minnesota) in the U.S. BACKGROUND: The most common congenital heart disease is PmVSD. Surgical repair is widely accepted, but still carries a small but definite risk of morbidity and mortality. METHODS: Between October 2003 and August 2004, a total of 35 patients with PmVSD underwent an attempt of transcatheter closure under transesophageal and/or intracardiac echocardiographic guidance. The median age was 7.7 years (range, 1.2 to 54.4 years) and median weight was 25 kg (range, 8.3 to 110 kg). The median Qp/Qs ratio was 1.8 (range, 1 to 4), and the median VSD size as assessed by echocardiography was 7 mm (range, 4 to 15 mm). RESULTS: The attempt to place a device was successful in 32 patients (91%). The median device size used was 10 mm (range, 6 to 16 mm). The complete closure rates by echocardiography at 10 min (transesophageal/intracardiac), 24 h, 1 month, and 6 months (transthoracic) were 47% (15/32), 63% (20/32), 78% (25/32), and 96% (27/28), respectively. The median fluoroscopy time was 36 min (range, 14 to 191 min), and the median total procedure time was 121 min (range, 67 to 276 min). Three patients (8.6%) had serious adverse events of complete heart block, peri-hepatic bleeding, and rupture of tricuspid valve chordae tendineae. No other patient encountered serious adverse events during the follow-up. CONCLUSIONS: Transcatheter closure of a PmVSD is technically feasible and seems safe enough in children over 8 kg in weight to warrant continuation of clinical trials to assess the long-term safety and efficacy.

AB - OBJECTIVES: This phase I study attempted to report the initial safety and efficacy results of transcatheter closure of perimembranous ventricular septal defects (PmVSDs) using the new Amplatzer Membranous VSD Occluder (AGA Medical Corp., Golden Valley, Minnesota) in the U.S. BACKGROUND: The most common congenital heart disease is PmVSD. Surgical repair is widely accepted, but still carries a small but definite risk of morbidity and mortality. METHODS: Between October 2003 and August 2004, a total of 35 patients with PmVSD underwent an attempt of transcatheter closure under transesophageal and/or intracardiac echocardiographic guidance. The median age was 7.7 years (range, 1.2 to 54.4 years) and median weight was 25 kg (range, 8.3 to 110 kg). The median Qp/Qs ratio was 1.8 (range, 1 to 4), and the median VSD size as assessed by echocardiography was 7 mm (range, 4 to 15 mm). RESULTS: The attempt to place a device was successful in 32 patients (91%). The median device size used was 10 mm (range, 6 to 16 mm). The complete closure rates by echocardiography at 10 min (transesophageal/intracardiac), 24 h, 1 month, and 6 months (transthoracic) were 47% (15/32), 63% (20/32), 78% (25/32), and 96% (27/28), respectively. The median fluoroscopy time was 36 min (range, 14 to 191 min), and the median total procedure time was 121 min (range, 67 to 276 min). Three patients (8.6%) had serious adverse events of complete heart block, peri-hepatic bleeding, and rupture of tricuspid valve chordae tendineae. No other patient encountered serious adverse events during the follow-up. CONCLUSIONS: Transcatheter closure of a PmVSD is technically feasible and seems safe enough in children over 8 kg in weight to warrant continuation of clinical trials to assess the long-term safety and efficacy.

UR - http://www.scopus.com/inward/record.url?scp=30344470520&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=30344470520&partnerID=8YFLogxK

U2 - 10.1016/j.jacc.2005.09.028

DO - 10.1016/j.jacc.2005.09.028

M3 - Article

VL - 47

SP - 319

EP - 325

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

SN - 0735-1097

IS - 2

ER -